Country-Specific Data and Priorities for Pertussis in Latin America: Recent Findings From the Global Pertussis Initiative - Takeaways - MDSpire

Country-Specific Data and Priorities for Pertussis in Latin America: Recent Findings From the Global Pertussis Initiative

  • By

  • Rolando Ulloa-Gutierrez

  • Daniela Hozbor

  • María L Avila-Aguero

  • Gabriela Echániz-Aviles

  • Angela Gentile

  • Juan Pablo Torres Torretti

  • Ulrich Heininger

  • Rudzani Muloiwa

  • Carl Heinz Wirsing von König

  • Kevin Forsyth

  • Tina Q Tan

  • May 13, 2025

  • 0 min

Share

  • 1

    The Global Pertussis Initiative assessed pertussis management in 10 Latin American countries, highlighting vaccination challenges and disease awareness.

  • 2

    Vaccination coverage remains suboptimal, particularly in pregnancy, despite recommendations for a 3-dose primary series and boosters.

  • 3

    Healthcare providers and the public need education on asymptomatic carriers of Bordetella pertussis and unique presentations in older populations.

  • 4

    The burden of pertussis can be reduced by improving vaccination rates, especially among pregnant individuals and adults.

  • 5

    The 2023 meeting aimed to update vaccination recommendations and discuss the impact of COVID-19 on pertussis vaccination coverage.

Original Source(s)

Country-Specific Data and Priorities for Pertussis in Latin America: Recent Findings From the Global Pertussis Initiative

  • by Rolando Ulloa-Gutierrez, Daniela Hozbor, María L Avila-Aguero, Gabriela Echániz-Aviles, Angela Gentile, Juan Pablo Torres Torretti, Ulrich Heininger, Rudzani Muloiwa, Carl Heinz Wirsing von König, Kevin Forsyth, Tina Q Tan

  • May 13, 2025

Related Content

RFK Jr. Takes Health Agenda on the Road

Touring Ohio, RFK Jr. highlights food quality and recovery services while steering attention away from vaccine controversies.

Measles Wild-Type Virus Detection Through Wastewater Surveillance in Sandoval County, New Mexico

RSV Prevention Tied to Lower Infant Acute Care Use

Data suggest fewer respiratory syncytial virus–associated hospitalizations and emergency department visits among the youngest infants during the second season of routine prevention product use.